Clinical Trials Related to Pembrolizumab

Related studies linked through entity extraction aliases.

Relative Bioavailability/Bioequivalence of Different Formulations of Selinexor, the Impact of Hepatic Impairment on Selinexor Pharmacokinetics, Tolerability and Antitumor Activity of Selinexor Combination Treatment

Status: COMPLETED
Phase: PHASE1/PHASE2

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Status: RECRUITING
Phase: PHASE2

Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer

Status: UNKNOWN
Phase: PHASE2

Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor Progression

Status: TERMINATED
Phase: PHASE2

GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1/PHASE2

Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

Status: COMPLETED
Phase: PHASE3

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Status: TERMINATED
Phase: PHASE1

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical Cancer

Status: UNKNOWN
Phase: PHASE2

Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors

Status: TERMINATED
Phase: PHASE1

Pembrolizumab in Early Stage Colon Cancer

Status: WITHDRAWN
Phase: PHASE2

Sacituzumab Govitecan In TNBC

Status: RECRUITING
Phase: PHASE2

Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma

Status: COMPLETED
Phase: PHASE2

A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2

Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile Cancer

Status: COMPLETED
Phase: PHASE2

Longitudinal Immune-phenotyping of HCC Following MK-3475

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE1

Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer

Status: ACTIVE_NOT_RECRUITING
Phase: PHASE3

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

Status: TERMINATED
Phase: PHASE3

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

Status: COMPLETED
Phase: PHASE3